Mylan Inc., a global pharmaceutical company, has launched telmisartan tablets USP, 20 mg, 40 mg and 80 mg, the generic version of Boehringer Ingelheim's Micardis tablets.

Mylan received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure.

Telmisartan tablets USP, 20 mg, 40 mg and 80 mg, had US sales of approximately $259.2 million for the 12 months ending March 31, 2014, according to IMS Health.

Currently, Mylan has 305 ANDAs pending FDA approval representing $107.2 billion in annual brand sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12 months ending December 31, 2013, according to IMS Health.